Emerald Bioscience to Participate in 29th Annual International Cannabinoid Research Symposium (ICRS)

via NEWMEDIAWIRE — Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that two posters related to its glaucoma therapeutic candidate, NB1111, will be presented at the 29th Annual Symposium of the International Cannabinoid Research Society. The symposium will be held June 29 – July 4, 2019 at the Marriott North in Bethesda, Maryland. Details of the posters are as follows:
Stock Symbols

Emerald Bioscience to Participate at the CannaStocks 2019 Q1 Investor Conference

via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Dr. Brian Murphy, CEO and Chief Medical Officer, will present at the CannaStocks 2019 Q1 Investor Conference on Wednesday, May 15, 2019 at 11 AM EDT at the OTC Markets Group Headquarters, 300 Vesey Street, New York, NY.
Stock Symbols

Emerald Bioscience Announces Ophthalmology Scientific Advisory Board Members

via NEWMEDIAWIRE — Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced members of the company’s Ophthalmology Scientific Advisory Board (OSAB). The purpose of the OSAB is to provide scientific and clinical guidance relating to EMBI’s proprietary cannabinoid-based drug platform to address diseases of the eye.
Stock Symbols

Emerald Bioscience to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that CEO and Chief Medical Officer Dr. Brian Murphy will present a corporate overview at the upcoming H.C. Wainwright Global Life Sciences Conference taking place at the Grosvenor House in London, UK.
Stock Symbols

Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act

via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that the Drug Enforcement Administration (DEA) has conducted a scientific review of the chemical structure of cannabidiol-­valine-hemisuccinate (CBDVHS) and determined that CBDVHS is not a regulated chemical nor controlled substance under the Controlled Substances Act.
Stock Symbols

Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments

<b></b><b>Name Change Reflects Company’s Focus on Advancing Cannabinoid-Based Therapeutics as a Member of the Emerald Group</b><b>Company to Trade on OTCQB Under Ticker EMBI at Market Open March 25, 2019</b>via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB:EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that it has changed (more…)

Stock Symbols

Imaging3 Update on Execution of Letter of Intent for Reverse Acquisition by Grapefruit Boulevard Investments, Inc.

Imaging3, Inc. (OTCQB:IGNG, “Imaging3” or the “Company”), a development stage company introducing disruptive technologies in the medical imaging industry, is updating and clarifying last week’s announcement that it has executed a non-binding letter of intent (“LOI”) to be acquired in a reverse acquisition (the “Acquisition”) by a privately held Los Angeles based cannabis company. The firm (identified as the Acquirer in the earlier announcement) is Grapefruit Boulevard Investments, Inc. (“GBI”) based in Westwood, Los Angeles, California. GBI holds California licenses to both manufacture and distribute cannabis products and is fully compliant with all applicable laws and regulations to operate such business. GBI has its extraction facility located in the Coachillin Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Rd., approximately 10 miles north of the center of Palm Springs. GBI obtained its California licenses in January of 2018 and commenced distribution of cannabis products in June of 2018. GBI’s goal is to become a seed to sale vertically integrated fully compliant cannabis and CBD product Company. As previously announced, on Thursday, March 7, GBI obtained its final permit and clearance from the Desert Hot Springs fire department to commence operation of an ethanol-based extraction laboratory at its facilities. As an update to the previous announcement, GBI intends to commence extraction operations the week of March 25, 2019.
Stock Symbols

Nemus Bioscience to Present at 31st Annual ROTH Conference

via NEWMEDIAWIRE — Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that CEO and Chief Medical Officer Dr. Brian Murphy will participate in a panel discussion, “Cannabinoid Pharmaceuticals,” at the 31st Annual ROTH Conference being held on March 17-19, 2019, at The Ritz Carlton, Laguna Niguel in Orange County, CA.
Stock Symbols